Amicus Therapeutics, Inc. (NASDAQ:FOLD) Undervalued by 34.7%

Adjust Comment Print

Therefore 89% are positive. Amicus Therapeutics's revenue for the quarter was up 50.0% compared to the same quarter past year. The rating was maintained by JP Morgan with "Overweight" on Tuesday, September 8. Amicus Therapeutics Inc now has $2.14B valuation. (NASDAQ:FOLD). Legal General Grp Public Ltd reported 55,411 shares stake.

When selecting potential stocks to buy, many investors want to find out what Wall Street professionals are thinking about the company beforehand - like what the average analyst rating is. The firm has "Outperform" rating given on Monday, October 5 by Leerink Swann. Tower Rech (Trc) reported 35 shares. $300,000 worth of Amicus Therapeutics, Inc. (FOLD) was a Buy - from a survey of 6 analysts. As per Thursday, April 14, the company rating was initiated by Robert W. Baird. At the moment, the average analyst rating for FOLD is Buy. Cowen & Co maintained the shares of FOLD in report on Tuesday, September 1 with "Buy" rating. A 5 analysts rate it as either a buy or a strong buy, while3 believe that investors should either steer clear of K or, if they already own its stock, sell it. As per Thursday, January 26, the company rating was maintained by Cowen & Co.

Sphera Funds Management Ltd decreased Amicus Therapeutics Inc (FOLD) stake by 20% reported in 2017Q2 SEC filing. The shares were sold at an average price of $13.61, for a total value of $642,568.93. The stock decreased 1.81% or $0.23 during the last trading session, reaching $12.51. About 379,053 shares traded. Perceptive Advisors LLC boosted its holdings in Amicus Therapeutics by 3.4% in the third quarter. Sectoral Asset Management Inc who had been investing in Amicus Therapeutics for a number of months, seems to be less bullish one the $2.08 billion market cap company. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. K trades with a P/S ratio of 1.85. It is down 12.45% since December 6, 2016 and is uptrending. It has underperformed by 4.25% the S&P500.


Investors sentiment increased to 1.23 in 2017 Q2. During the same quarter last year, the company earned ($0.33) earnings per share. analysts anticipate that Amicus Therapeutics, Inc. will post -1.56 EPS for the current fiscal year. It improved, as 15 investors sold FOLD shares while 38 reduced holdings.

PERCEPTIVE ADVISORS LLC raised its stake in Amicus Therapeutics, Inc. 168.77 million shares or 4.30% more from 161.81 million shares in 2017Q1 were reported. Finally, Cowen reissued a "buy" rating and issued a $16.00 price objective on shares of Amicus Therapeutics in a research report on Monday, August 14th. (NASDAQ:FOLD) shares were sold by Barth Jay. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company's stock worth $91,821,000 after buying an additional 430,486 shares in the last quarter. Rock Springs Mgmt Lp stated it has 0.39% of its portfolio in Amicus Therapeutics, Inc. Leerink Swann reaffirmed an "outperform" rating and set a $17.00 target price (down previously from $18.00) on shares of Amicus Therapeutics in a research note on Saturday, September 16th. Palo Alto Ltd Liability holds 7.94M shares or 3.73% of its portfolio. Morgan Stanley reported 7.25M shares stake. Schwab Charles Invest Inc holds 592,934 shares. Hap Trading Ltd Co owns 0.05% invested in Amicus Therapeutics, Inc. Shares of K have uptrended 0.56% in the past three months, while the S&P 500 has moved -4.32% in that time. Zacks has invested 0% in Amicus Therapeutics, Inc. The New York-based Sio Capital Management Llc has invested 3.32% in the stock. (NASDAQ:FOLD). Manufacturers Life Co The owns 111,568 shares or 0% of their USA portfolio. VANGUARD GROUP INC also announced increased position in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Aperio Llc, a California-based fund reported 13,986 shares.

Since June 15, 2017, it had 0 buys, and 1 sale for $300,000 activity. Its down 0.15, from 1.15 in 2017Q1. Cordasco Ntwk reported 140 shares. It has ditched 6.53 million shares. Fayez Sarofim & Communications reported 0.01% in Freeport-McMoRan Inc.


Csu Producer Resources Inc. holds 12.94% of its portfolio in Norfolk Southern Corporation for 21,400 shares. Nikko Asset Mngmt Americas invested 1.32% of its portfolio in Freeport-McMoRan Inc. 42,400 are owned by Trexquant Invest Limited Partnership. Marshall Wace Llp holds 177,205 shares. Tudor Investment Et Al invested in 0% or 12,332 shares. Amicus Therapeutics had 20 analyst reports since August 18, 2015 according to SRatingsIntel. The firm earned "Buy" rating on Monday, August 31 by Deutsche Bank. The firm has "Neutral" rating by Goldman Sachs given on Wednesday, March 30. The other 8, though not evenly; between analysts who think you should buy Kellogg Company versus those who think you should sell it. Corporate insiders own 3.40% of the company's stock. The stock has "Outperform" rating by Credit Suisse on Thursday, September 22. Chardan Capital Markets downgraded the shares of FOLD in report on Wednesday, September 16 to "Neutral" rating. The stock of Freeport-McMoRan Inc.

Analysts await Puma Biotechnology, Inc.

Wall Street analysts, on average, are forecasting the company's EPS to be -0.29, compared to -0.42 reported in the same quarter a year ago. FCX's profit will be $607.99M for 8.54 P/E if the $0.42 EPS becomes a reality. After $1.75 actual EPS reported by Norfolk Southern Corporation for the previous quarter, Wall Street now forecasts -10.86% negative EPS growth. (NASDAQ:DXCM) stake by 13,300 shares and now owns 84,500 shares. Healthequity Inc (NASDAQ:HQY) was raised too.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Comments